From the Guidelines
The maximum dose of glipizide immediate release (IR) is 40 mg.
Key Points
- The evidence from the study 1 provides a clear maximum approved daily dose for glipizide IR.
- According to the study, the maximum approved daily dose for glipizide IR is 40 mg, with a dosage strength of 10 mg.
- This information is crucial for guiding the treatment of patients with diabetes, ensuring that they receive the appropriate dose of glipizide IR to manage their condition effectively.
- It's essential to note that the maximum dose may vary depending on the specific formulation, in this case, glipizide IR, which has a different maximum dose compared to the extended release (XL/ER) formulation.
- The study 1 also provides information on the median monthly average wholesale price (AWP) and National Average Drug Acquisition Cost (NADAC) for glipizide IR, which can be useful for healthcare providers and patients when making decisions about treatment options.
From the FDA Drug Label
DOSAGE AND ADMINISTRATION ... The maximum recommended once daily dose is 15 mg. Doses above 15 mg should ordinarily be divided and given before meals of adequate caloric content. The maximum recommended total daily dose is 40 mg
- The maximum dose of glipizide immediate release (IR) is 40 mg per day, with a maximum once daily dose of 15 mg 2.
From the Research
Maximum Dose of Glipizide Immediate Release (IR)
- The maximum dose of glipizide immediate release (IR) is 40 mg/day, as mentioned in the study 3 which compared the efficacy of maximum dose glyburide and glipizide in patients with non-insulin-dependent diabetes mellitus (NIDDM).
- Another study 4 also mentions a daily dose of 5, 20, or 40 mg of immediate-release glipizide, confirming that 40 mg is the maximum dose.
- No other studies provided information on the maximum dose of glipizide IR, but the consistency between these two studies suggests that 40 mg/day is the established maximum dose.
- It is worth noting that the dosing information for glipizide IR is not explicitly stated in the other studies 5, 6, 7, which focused on comparisons with extended-release or sustained-release formulations.